ose-127
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 19, 2018 (NCT03980080)
Timeline
Indications
Mechanism of action
- Interleukin-7INHIBITOR
Interleukin-7 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04605978 | Phase 2 | Dec 7, 2020 | Servier |
| NCT04882007 | Phase 2 | Oct 2, 2020 | OSE Immunotherapeutics |
| NCT03980080 | Phase 1 | Dec 19, 2018 | OSE Immunotherapeutics, Servier |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | For profit | 2 | 2 | 2 | 2018 |
| Servier | For profit | 2 | 1 | 2 | 2018 |
2 organizations
Page 1 / 1